TATAA Biocenter Partners with SimplicityBio
News Oct 26, 2016
TATAA Biocenter has partnered with SimplicityBio to offer complete solutions for biomarker discovery, signature optimization and validation. The partnership offers a complete solution comprising biomarker discovery, assay and protocol optimization, analytical validation, standardization, and clinical validation leading to robust and reliable biomarker signatures for diagnostics, prognostics and theranostics. Platforms include microarrays, qPCR, dPCR and NGS and virtually any kind of biomarkers with emphasis on mRNA, microRNA, lncRNA, DNA (SNP, CNV, methylation, cfDNA), protein and circulating tumor cells.
“Leveraging on our experience of quality control and standardization of molecular analyses we design experimental protocols and generate data of highest quality for our clients. Combining our data with first class biomarker analyses provided by SimplicityBio, we provide our clients with complete solutions” says Mikael Kubista, President of TATAA Biocenter.
"We’re always looking to partner with innovative companies that are true leaders in the genomic services industry, and TATAA Biocenter is exactly that. TATAA Biocenter supports clients with design and validation of assays and generates genomic data of highest quality based on their accredited pipelines. Those data are perfect inputs for our biomarker discovery and modelling pipelines” said Dr. Matthew Hall CSO of SimplicityBio. Together we offer our clients the most powerful platform for biomarker discover, validation and confirmation currently available.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.